2026 Q1 -tulosraportti
60 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,58%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenRemember to drink plenty of water if you are going to expose yourselves to Foundayo!
Only ignorant patients and miserable doctors are on the Foundayo team. Who in the world would want worse weight loss, a 14 times greater risk of stopping due to side effects, perhaps get liver damage, compared to better weight loss, fewer side effects, help against cardiovascular diseases and fatty liver, perhaps also against alcohol dependence and depression etc. Well, that's just completely wild.
·6 t sittenNovo has shifted from primarily conducting share buybacks to the majority being dividends. This meets virtually no criticism, presumably because foreigners simply refrain from buying it if they lack the resources to reclaim the overpaid tax. The Treasury is well satisfied, but the stock is tax-wise hopeless for foreigners to own, and Novo's ownership circle will have to address that sooner or later. DK has absurdly high dividend withholding tax, and the large mastodons like Novo and Coloplast pay out dividends in large quantities. It is certainly underlying funds that are interested in fixed payments, but it's no use if one also wants to be shareholder-friendly towards foreigners.- ·18 t sitten · MuokattuIt seems the market completely forgot that the Medicare agreement with the USA was what was received in "return" for adjusting prices. That is, much higher volume, broader public coverage in exchange for prices being adjusted. The market only heard the word "price pressure" From the Q1 report. In November 2025, Novo Nordisk entered into an agreement with the US government to expand access to GLP-1 preparations and lower costs. Under the "Most Favoured Nations" (MFN) agreement, semaglutide medicines, including Wegovy and Ozempic, will gain broader access and better affordability through Medicare Part D, Medicaid, and directly to patients' out-of-pocket payments. Coverage of obesity medication under Medicare Part D is planned via a pilot program, encompassing a majority of eligible recipients, with expected implementation from July 1, 2026.
·1 päivä sittenNew analysis, taking into account both technical and fundamental factors: After a thorough multifactor analysis, I have now updated my model for Novo. I have combined discounted cash flow DCF with comparable company multiples EV EBITDA and P E forward as well as technical overlay via Fibonacci retracement levels Ichimoku Cloud and MACD histogram divergence fundamental highlights include Ozempic and Wegovy which continue with hyperbolic sales growth driven by GLP 1 pipeline expansion and label expansions into new indications NASH Alzheimer OSA while gross margin expansion is over 200 bps annually due to capacity ramp up in Kalundborg and new production facilities with strong free cash flow conversion and ROIC over 45 percent the company is a real economic moat monster with patent cliff hedging via next gen oral semaglutide and CagriSema technically the stock has broken out of an 18-month ascending triangle with increasing volume profile RSI shows bullish divergence on weekly timeframe and 200-day EMA acts as strong dynamic support while Bollinger Band squeeze indicates impending upward volatility expansion my proprietary hybrid model which weighs both quantitative sentiment analysis from earnings calls and order flow toxicity now points to a fair value of 646 kr by the end of 2027 this corresponds to a CAGR of 18 to 22 percent from current levels including dividend reinvestment and share buyback accretion bull case if CagriSema becomes a blockbuster can go towards 820 to 950 kr while bear case still lies comfortably above 500 kr I have therefore increased my position further with a collar strategy to protect downside while retaining upside what do you think are you still bullish on Novo or do you see peak GLP 1 hype already priced in. Well, now the nurse is coming with my medicine, so now I don't have time to write more
A bit shorter analysis Mr. Stock expert, I have delicate skin on my fingers, they can't stand endless scrolling. But why, now that your analysis is so long, not just talk it up to 1,000 as some of us remember it being when times were different.......
·1 päivä sittenDo we think E Lilly will have a a downturn for the first time? They can't talk their way out of this one.. what do you others think, that must be a huge plus for Novo Nordisk
Agreed! The same day Novo presents its Q2 on August 5th, Eli Lilly also does. It will be difficult to explain away so few prescriptions/sales over so many weeks/months for Lilly.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
60 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,58%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenRemember to drink plenty of water if you are going to expose yourselves to Foundayo!Only ignorant patients and miserable doctors are on the Foundayo team. Who in the world would want worse weight loss, a 14 times greater risk of stopping due to side effects, perhaps get liver damage, compared to better weight loss, fewer side effects, help against cardiovascular diseases and fatty liver, perhaps also against alcohol dependence and depression etc. Well, that's just completely wild.
- ·6 t sittenNovo has shifted from primarily conducting share buybacks to the majority being dividends. This meets virtually no criticism, presumably because foreigners simply refrain from buying it if they lack the resources to reclaim the overpaid tax. The Treasury is well satisfied, but the stock is tax-wise hopeless for foreigners to own, and Novo's ownership circle will have to address that sooner or later. DK has absurdly high dividend withholding tax, and the large mastodons like Novo and Coloplast pay out dividends in large quantities. It is certainly underlying funds that are interested in fixed payments, but it's no use if one also wants to be shareholder-friendly towards foreigners.
- ·18 t sitten · MuokattuIt seems the market completely forgot that the Medicare agreement with the USA was what was received in "return" for adjusting prices. That is, much higher volume, broader public coverage in exchange for prices being adjusted. The market only heard the word "price pressure" From the Q1 report. In November 2025, Novo Nordisk entered into an agreement with the US government to expand access to GLP-1 preparations and lower costs. Under the "Most Favoured Nations" (MFN) agreement, semaglutide medicines, including Wegovy and Ozempic, will gain broader access and better affordability through Medicare Part D, Medicaid, and directly to patients' out-of-pocket payments. Coverage of obesity medication under Medicare Part D is planned via a pilot program, encompassing a majority of eligible recipients, with expected implementation from July 1, 2026.
- ·1 päivä sittenNew analysis, taking into account both technical and fundamental factors: After a thorough multifactor analysis, I have now updated my model for Novo. I have combined discounted cash flow DCF with comparable company multiples EV EBITDA and P E forward as well as technical overlay via Fibonacci retracement levels Ichimoku Cloud and MACD histogram divergence fundamental highlights include Ozempic and Wegovy which continue with hyperbolic sales growth driven by GLP 1 pipeline expansion and label expansions into new indications NASH Alzheimer OSA while gross margin expansion is over 200 bps annually due to capacity ramp up in Kalundborg and new production facilities with strong free cash flow conversion and ROIC over 45 percent the company is a real economic moat monster with patent cliff hedging via next gen oral semaglutide and CagriSema technically the stock has broken out of an 18-month ascending triangle with increasing volume profile RSI shows bullish divergence on weekly timeframe and 200-day EMA acts as strong dynamic support while Bollinger Band squeeze indicates impending upward volatility expansion my proprietary hybrid model which weighs both quantitative sentiment analysis from earnings calls and order flow toxicity now points to a fair value of 646 kr by the end of 2027 this corresponds to a CAGR of 18 to 22 percent from current levels including dividend reinvestment and share buyback accretion bull case if CagriSema becomes a blockbuster can go towards 820 to 950 kr while bear case still lies comfortably above 500 kr I have therefore increased my position further with a collar strategy to protect downside while retaining upside what do you think are you still bullish on Novo or do you see peak GLP 1 hype already priced in. Well, now the nurse is coming with my medicine, so now I don't have time to write moreA bit shorter analysis Mr. Stock expert, I have delicate skin on my fingers, they can't stand endless scrolling. But why, now that your analysis is so long, not just talk it up to 1,000 as some of us remember it being when times were different.......
- ·1 päivä sittenDo we think E Lilly will have a a downturn for the first time? They can't talk their way out of this one.. what do you others think, that must be a huge plus for Novo NordiskAgreed! The same day Novo presents its Q2 on August 5th, Eli Lilly also does. It will be difficult to explain away so few prescriptions/sales over so many weeks/months for Lilly.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
60 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
3,58%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenRemember to drink plenty of water if you are going to expose yourselves to Foundayo!Only ignorant patients and miserable doctors are on the Foundayo team. Who in the world would want worse weight loss, a 14 times greater risk of stopping due to side effects, perhaps get liver damage, compared to better weight loss, fewer side effects, help against cardiovascular diseases and fatty liver, perhaps also against alcohol dependence and depression etc. Well, that's just completely wild.
- ·6 t sittenNovo has shifted from primarily conducting share buybacks to the majority being dividends. This meets virtually no criticism, presumably because foreigners simply refrain from buying it if they lack the resources to reclaim the overpaid tax. The Treasury is well satisfied, but the stock is tax-wise hopeless for foreigners to own, and Novo's ownership circle will have to address that sooner or later. DK has absurdly high dividend withholding tax, and the large mastodons like Novo and Coloplast pay out dividends in large quantities. It is certainly underlying funds that are interested in fixed payments, but it's no use if one also wants to be shareholder-friendly towards foreigners.
- ·18 t sitten · MuokattuIt seems the market completely forgot that the Medicare agreement with the USA was what was received in "return" for adjusting prices. That is, much higher volume, broader public coverage in exchange for prices being adjusted. The market only heard the word "price pressure" From the Q1 report. In November 2025, Novo Nordisk entered into an agreement with the US government to expand access to GLP-1 preparations and lower costs. Under the "Most Favoured Nations" (MFN) agreement, semaglutide medicines, including Wegovy and Ozempic, will gain broader access and better affordability through Medicare Part D, Medicaid, and directly to patients' out-of-pocket payments. Coverage of obesity medication under Medicare Part D is planned via a pilot program, encompassing a majority of eligible recipients, with expected implementation from July 1, 2026.
- ·1 päivä sittenNew analysis, taking into account both technical and fundamental factors: After a thorough multifactor analysis, I have now updated my model for Novo. I have combined discounted cash flow DCF with comparable company multiples EV EBITDA and P E forward as well as technical overlay via Fibonacci retracement levels Ichimoku Cloud and MACD histogram divergence fundamental highlights include Ozempic and Wegovy which continue with hyperbolic sales growth driven by GLP 1 pipeline expansion and label expansions into new indications NASH Alzheimer OSA while gross margin expansion is over 200 bps annually due to capacity ramp up in Kalundborg and new production facilities with strong free cash flow conversion and ROIC over 45 percent the company is a real economic moat monster with patent cliff hedging via next gen oral semaglutide and CagriSema technically the stock has broken out of an 18-month ascending triangle with increasing volume profile RSI shows bullish divergence on weekly timeframe and 200-day EMA acts as strong dynamic support while Bollinger Band squeeze indicates impending upward volatility expansion my proprietary hybrid model which weighs both quantitative sentiment analysis from earnings calls and order flow toxicity now points to a fair value of 646 kr by the end of 2027 this corresponds to a CAGR of 18 to 22 percent from current levels including dividend reinvestment and share buyback accretion bull case if CagriSema becomes a blockbuster can go towards 820 to 950 kr while bear case still lies comfortably above 500 kr I have therefore increased my position further with a collar strategy to protect downside while retaining upside what do you think are you still bullish on Novo or do you see peak GLP 1 hype already priced in. Well, now the nurse is coming with my medicine, so now I don't have time to write moreA bit shorter analysis Mr. Stock expert, I have delicate skin on my fingers, they can't stand endless scrolling. But why, now that your analysis is so long, not just talk it up to 1,000 as some of us remember it being when times were different.......
- ·1 päivä sittenDo we think E Lilly will have a a downturn for the first time? They can't talk their way out of this one.. what do you others think, that must be a huge plus for Novo NordiskAgreed! The same day Novo presents its Q2 on August 5th, Eli Lilly also does. It will be difficult to explain away so few prescriptions/sales over so many weeks/months for Lilly.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt